PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Sirolimus (Primary) ; TAS 119 (Primary)
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 12 Dec 2023 Results assessing Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 26 Apr 2022 Status changed from not yet recruiting to recruiting, according to a VITRAC Therapeutics media release.
- 12 Apr 2022 Inclusion criteria has been updated to remove the maximum age limit of 60 years.